At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Prospective Phase II Study of Concurrent Chemoradiotherapy Combined With Toripalimab and Surufatinib in the Treatment of Limited-Stage Small Cell Lung Cancer
In Brief
A Phase 2 clinical trial evaluating Chemotherapy, Immunotherapy, and 4 other interventions for Toripalimab and 3 related conditions. Currently recruiting, targeting 47 participants across 1 site.
Detailed Summary
Based on the preclinical rationale for combining surufatinib with immunotherapy, and the clinical efficacy observed with surufatinib in extensive-stage small cell lung cancer (ES-SCLC), the investigators hypothesize that incorporating surufatinib into the ADRIATIC regimen could further enhance survival in LS-SCLC. To evaluate this approach, the investigators plan to conduct a single-arm Phase II study to explore the safety and efficacy of concurrent chemoradiotherapy combined with toripalimab and surufatinib in treating LS-SCLC.
Study Details
Timeline
Interventions
Etoposide combined with cisplatin or carboplatin, administered every three weeks for a total of four cycles.
Toripalimab was administered concurrently with chemotherapy, every three weeks for four cycles.
Oral surufatinib 200 mg once daily (q.d.), given on days 1-14 of each chemotherapy cycle.
Thoracic radiotherapy will begin no later than the start of the third chemotherapy cycle.
PCI is recommended after the completion of chemoradiotherapy.
Patients achieving complete response (CR), partial response (PR), or stable disease (SD) following chemoradiotherapy will receive consolidation therapy. Toripalimab: 240 mg intravenously on day 1, every three weeks. Surufatinib: 200 mg orally on days 1-14, every three weeks.